Chiusura precedente | 2,7200 |
Aperto | 2,7000 |
Denaro | 2,8200 x 200 |
Lettera | 2,8500 x 100 |
Min-Max giorno | 2,6600 - 2,8300 |
Intervallo di 52 settimane | 1,6700 - 5,2500 |
Volume | |
Media Volume | 183.104 |
Capitalizzazione | 114,264M |
Beta (5 anni mensile) | 1,83 |
Rapporto PE (ttm) | 20,14 |
EPS (ttm) | 0,1400 |
Prossima data utili | 09 mag 2024 - 13 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 4,25 |
PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”). Pursuant to that certain Stock Purchase Agreement entered into on Septem
PALO ALTO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. (Nasdaq: ORMP, “Oramed”) and Sorrento executed non